Well said TDA. I joined in very early for the very same reasons and certainly consider a future SP in dollars not cents as a probability not a dream. The timing is the main question here.
We all know the difficulty to both execute a great R&D/Commercialisation plan and to deliver value for SH at the same time. It's tough for very small caps, especially in biotech and in Australia. Being able to manage long term and short term expectations is an art.
In a way, the success of Viralytics has given me some hope that RGS's value could be soon recognised by either the stock market or a buyer.
The reason is very simple: if the announced strategy for Progenza is delivered on time (i.e. patents, commercial partnerships, milestones payments, trials and sales), then it opens a very straight forward and efficient pathway to market for Sygenus, which has even more potential that Progenza.
In the meantime, it is a pleasure to finally see a nice ride on the back of the so-important granted patent in the US.
When a commercial partnership is finally announced for Progenza in Japan, I think SP will reach 0.35 easily if not 0.5.
For 0.7/0.8 will have to wait a bit longer.
RGS Price at posting:
20.0¢ Sentiment: Buy Disclosure: Held
